glucocorticoid-induced osteoporosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with systemic autoimmune diseases who commenced glucocorticoid therapy with prednisolone at doses over 15 mg daily 2. Patients who agree with this study
Exclusion criteria
Exclusion criteria: 1. Patients who have received romosozumab or denosumab or bisphosphonate 2. Patients with contraindication for romosozumab or denosumab or bisphosphonate 3. Patients with severe renal dysfunction (eGFR < 30mL/min/1.73m2) 4. Patients who is currently pregnant, breastfeeding or willing to get pregnant 5. Patients who do not give consent to the study 6. Patients who are judged to be inappropriate by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of bone mineral density at 12 months after initiation of glucocorticoid therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of bone mineral density at 36 months after initiation of glucocorticoid therapy, the change of bone metabolism markers and adverse events during the observation period | — |
Countries
Japan
Contacts
Toho University School of Medicine Division of Rheumatology, Department of Internal Medicine